Bio

Gaurav Aggarwal, M.D. comes to Vivo with prior experience investing in private and public biopharmaceutical and medical device companies across the spectrum of development. He previously served as Managing Director with Investor Growth Capital, Partner with Panorama Capital and Associate at JPMorgan Partners. He was an investor and previously served on the boards of Auspex Pharmaceuticals (acquired by Teva), Hyperion Therapeutics (acquired by Horizon), NextWave Pharmaceuticals (acquired by Pfizer), Piramed (acquired by Roche) and Flowcardia (acquired by CR Bard). Other successful investments include Amarin, ISTA Pharmaceuticals and Spinal Concepts. In addition to his role as an investor, Gaurav was the Chief Business Officer of Ocera Therapeutics, a publicly traded clinical stage company developing therapies for orphan liver conditions. Gaurav received his M.D. from Columbia University, College of Physicians & Surgeons, and his B.S. in Agricultural Economics from Cornell University.